Zinc Acetate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Zinc Acetate
- Zinc Acetate: From Nutritional Zinc Supply to Severe Nonproliferative Diabetic Retinopathy
Zinc Acetate: From Nutritional Zinc Supply to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Zinc acetate is a zinc salt. In South Africa it appears in registered products that are mainly parenteral nutrition infusions, and no approved indication text is recorded in the data provided. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration data (registered products are infusion and total parenteral nutrition products) |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 5 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Zinc is a cofactor of copper/zinc superoxide dismutase (SOD) and is abundant in the retina. It could therefore modulate oxidative stress in diabetic retinal injury.
Diabetic retinopathy involves oxidative and inflammatory damage to retinal vessels, so an antioxidant role is biologically plausible. This link is unverified. The provided data contains no trial or publication that tests it, and the high score reflects knowledge-graph patterns rather than clinical proof.
The same reasoning applies to the broader entry “diabetic retinopathy” (rank 3, score 99.92%), which also has no clinical or literature evidence.
Clinical Trial Evidence
Currently no related clinical trials registered for severe nonproliferative diabetic retinopathy. No SANCTR or PACTR records were provided.
For context, one trial exists for a lower-ranked prediction (bronchitis) and gives only indirect support:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03309995 | Not applicable | Completed | 87 | Blinded randomised trial of zinc acetate lozenges (13 mg elemental zinc) for recovery from the common cold. It studied a different disease and is not a bronchitis trial. |
Literature Evidence
Currently no related literature available for severe nonproliferative diabetic retinopathy.
Lower-ranked predictions have only weak or indirect literature. For bronchitis, the two papers were a zinc oxide nanoparticle laboratory study and a poultry study, and neither is clinical evidence for zinc acetate. For urinary tract infection, one older RCT gave zinc supplementation in sickle cell disease and looked at overall infection incidence, not urinary infections specifically (PMID 10398312, 1999, American Journal of Hematology).
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 32/34/0561 | Prograf ampoule 1ml | Infusion | Not stated |
| 41/25/0757 | Nutriflex Lipid Peri | Infusion | Not stated |
| 49/25/0065 | Nutriflex Omega Specialized | Infusion | Not stated |
| 41/25/0757 | Nutriflex lipid peri 1875ml | TPN | Not stated |
| 41/25/0759 | Nutriflex lipid special 625ml | TPN | Not stated |
Notes:
- No approved indication text was supplied for any registration, and Essential Medicines List (EML) status is not recorded.
- Registration 41/25/0757 appears twice, for two pack presentations.
- All listed forms are parenteral (infusion or TPN). No oral or topical zinc acetate product is registered in this dataset.
- The input lists TFDA as its regulatory source. The registrations should be checked against the SAHPRA register. The Prograf entry (tacrolimus brand) should also be verified, as zinc acetate is not an obvious ingredient.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
No drug interaction records were found for this drug in the data provided.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but there are no clinical trials or publications for severe nonproliferative diabetic retinopathy (L5). The only rationale is a plausible antioxidant mechanism. The registered products are parenteral nutrition formulations, and route compatibility with an eye indication has not been assessed.
To proceed, the following is needed:
- Preclinical or clinical studies of zinc in diabetic retinopathy, starting with a systematic literature search
- Mechanism of action data from DrugBank
- SAHPRA Professional Information (warnings and contraindications), which is a blocking gap for safety screening
- Verified registration details and approved indications for the listed products
- An assessment of which route and formulation would suit a retinal indication
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.